Ask AI
Thrombosis in ET and PV

CME

High Suspicion, Better Outcomes: Evaluating Thrombotic Events for Underlying ET or PV

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: May 14, 2026

Expiration: November 13, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Guy A, Morange P-E, James C. How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms. Blood. 2025;145:1769-1779.
  2. Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19:184.
  3. Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317-325.
  4. Barbui T, Ginazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176-2184.
  5. Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2013;121:360-368.
  6. Sozer S, Fiel MI, Schiano T, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246-5249.
  7. Teofili L, Martini M, Iachininoto MG, et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011;117:2700-2707.
  8. Gerds AT, Mesa R, Burke JM, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143:1646-1655.
  9. Middledorp S, Nieuwlaat R, Kreuziger LB, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances. 2023;7:7101-7138.